Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.
Moody's downgrades US credit rating over rising debt, signaling broader market concerns about the nation's fiscal trajectory.
Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.
Moody's downgrades US credit rating over rising debt, signaling broader market concerns about the nation's fiscal trajectory.